Abstract

The Consortium's Early Phase Clinical Research Support program provides funding for dedicated research nurse and data manager support, and other costs associated with generation of preliminary data, for the coordination and implementation of early phase cancer clinical trials initiated by Consortium members. Studies selected for EPCRS funding are high priority trials with the potential to improve diagnosis, prevention or treatment of cancer. This program will accomplish the following objectives: 1. Continue to expand the Consortium's phase I clinical trials portfolio through support of innovative, proof-of-principle cancer studies to evaluate new agents, medical procedures and devices in order to provide the data necessary to apply for funding of later phase studies. 2. Strengthen the clinical research portfolio of established CCSG solid tumor programs as well as solid tumor programs with sufficient readiness to be evaluated for CCSG program development during the new project period. 3. Stimulate new novel and collaborative early phase trials across the Consortium that incorporate imaging and radiation science, areas in which Consortium members have significant strength.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015704-44S3
Application #
9842486
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
2019-01-01
Budget End
2019-12-31
Support Year
44
Fiscal Year
2019
Total Cost
Indirect Cost

  Institution

Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109

  Publications

Paulson, K G; Voillet, V; McAfee, M S et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nat Commun 9:3868
Puronen, Camille E; Cassaday, Ryan D; Stevenson, Philip A et al. (2018) Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation-Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biol Blood Marrow Transplant 24:2211-2215
Gavvovidis, Ioannis; Leisegang, Matthias; Willimsky, Gerald et al. (2018) Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus. Clin Cancer Res 24:3644-3655
Rosenthal, Elisabeth A; Shirts, Brian H; Amendola, Laura M et al. (2018) Rare loss of function variants in candidate genes and risk of colorectal cancer. Hum Genet 137:795-806
Verboon, Jeffrey M; Decker, Jacob R; Nakamura, Mitsutoshi et al. (2018) Correction: Wash exhibits context-dependent phenotypes and, along with the WASH regulatory complex, regulates Drosophila oogenesis (doi:10.1242/211573). J Cell Sci 131:
Witzky, Anne; Hummels, Katherine R; Tollerson 2nd, Rodney et al. (2018) EF-P Posttranslational Modification Has Variable Impact on Polyproline Translation in Bacillus subtilis. MBio 9:
Davis, Ryan J; Gönen, Mehmet; Margineantu, Daciana H et al. (2018) Pan-cancer transcriptional signatures predictive of oncogenic mutations reveal that Fbw7 regulates cancer cell oxidative metabolism. Proc Natl Acad Sci U S A 115:5462-5467
Sillah, Arthur; Watson, Nathaniel F; Schwartz, Stephen M et al. (2018) Sleep apnea and subsequent cancer incidence. Cancer Causes Control 29:987-994
Hay, Kevin A; Turtle, Cameron J (2018) CD19-specific chimeric antigen receptor-modified (CAR)-T cell therapy for the treatment of chronic lymphocytic leukemia in the ibrutinib era. Immunotherapy 10:251-254
Ginos, Bigina N R; Navarro, Sandi L; Schwarz, Yvonne et al. (2018) Circulating bile acids in healthy adults respond differently to a dietary pattern characterized by whole grains, legumes and fruits and vegetables compared to a diet high in refined grains and added sugars: A randomized, controlled, crossover feeding stud Metabolism 83:197-204

Showing the most recent 10 out of 1267 publications